Experimental gel could become the first approved treatment for cancer wounds Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/experimental-gel-could-become-the-first-approved-treatment-for-cancer-wounds-16906?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9m3w8PWxf50muvPP9_UnJwzU-L3vM7r7ZxxUAr_3Rt-q8ORWzbTHPqmwPRT-lWTemWaJ6OTC9XDDfOkLuQUjp2pkqkTg&_hsmi=421891039&utm_content=421891039&utm_source=hs_email In December 2025, Vyome Therapeutics announced compelling Phase 2 results for VT-1953, its investigational topical immunomodulator, in patients with malignant fungating wounds (MFWs) — a rare but highly distressing complication that affects an estimated five to 14 percent of individuals with advanced cancer.